William Blair Comments on Pyxis Oncology FY2027 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) recently had its FY2027 earnings per share (EPS) estimates analyzed by research analysts from William Blair. In a report published on March 18th, analyst A. Hsieh forecasted that the company will record an earnings loss of $1.27 per share for fiscal year 2027. William Blair has also assigned a "Market Perform" rating to the stock.

The current consensus among analysts for the company's full-year earnings stands at a loss of $1.04 per share.

Stock Ratings and Research Reports

In addition to the insights from William Blair, other equity research analysts have shared their evaluations of Pyxis Oncology. For instance, Royal Bank of Canada has reaffirmed its "outperform" rating for the stock, with a target price set at $8.00. Meanwhile, HC Wainwright has also reaffirmed a "buy" rating but has set a lower target price of $5.00. Currently, among all analysts covering the stock, one has issued a hold rating while five analysts have rated it as a buy. According to MarketBeat.com, Pyxis Oncology holds an average rating of "Moderate Buy" along with an average target price of $9.20.

Current Market Performance

The trading performance of Pyxis Oncology shares has shown a minor increase of 0.9% recently, with shares opening at $1.07 on Thursday. Over the past year, the stock has fluctuated, reaching a low of $0.99 and a peak of $6.18. Its market capitalization is recorded at $63.63 million, and the stock has a P/E ratio of -1.04, indicating that it operates at a loss. The fifty-day simple moving average for the stock is $1.34, while the 200-day average stands at $2.39.

The company also recently released its earnings report on March 18th, where it reported an EPS loss of $0.32 for the previous quarter, which was slightly better than the consensus estimate of a loss of $0.33.

Institutional Investor Activity

Changes in positions by institutional investors have been noteworthy. In the third quarter, Intech Investment Management LLC acquired a new stake in Pyxis Oncology valued at approximately $55,000. ProShare Advisors LLC also made a new investment during the fourth quarter, totaling about $26,000. Moreover, MetLife Investment Management LLC boosted its stake in Pyxis by 41.1% during the third quarter, now holding 18,818 shares valued at $69,000. Ameriprise Financial Inc. and Caption Management LLC also joined in by making new investments worth around $35,000 each in the fourth quarter. Currently, institutional investors own about 39.09% of the company's stock.

Company Overview

Pyxis Oncology, Inc. focuses on developing innovative therapeutics to combat cancer. The company's lead product candidate is PYX-201, an investigational antibody-drug conjugate (ADC) that is in Phase 1 clinical testing, targeted at patients with relapsed or refractory solid tumors. Additionally, its immuno-oncology (IO) lead candidate, PYX-106, is a fully human IgG1 Siglec-15-targeting antibody currently in Phase 1 trials aimed at treating patients with advanced solid tumors.

Earnings, Stocks, Analysis